Published online Nov 2, 2014. doi: 10.5314/wjd.v3.i4.76
Revised: August 28, 2014
Accepted: September 16, 2014
Published online: November 2, 2014
Core tip: We review and summarize the published data regarding the efficacy and safety of anti-tumor necrosis factor-alpha and anti-interleukin-12/23 therapies in patients with psoriasis and liver diseases, with special reference to hepatitis C, hepatitis B, non-alcoholic fatty liver disease, and fatty liver disease. Data collected and revised up to December 2013.